Navigation Links
Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
Date:10/26/2010

BASKING RIDGE, N.J., Oct. 26 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Oppenheimer 21st Annual Healthcare Conference.  Dr. Mazzo's presentation will be given at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010 at 10:45 a.m. EDT in the Louis XVI Room.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system, REG1.ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007). &
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
2. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
3. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
4. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
5. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
6. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
7. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
8. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
9. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
10. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
11. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... for the American Society for Reproductive Medicine (ASRM), a ... in reproductive medicine. In his new role as ... executive board and will have a voice in furthering ... actively supported ASRM since 1984 when he joined while ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... a research collaboration to improve insect control in corn and soybeans. ... ... NC (Vocus) January 15, 2009 -– DuPont and Athenix today announced ... in corn and soybeans. Under the agreement, DuPont business ...
... Jan. 15 Regado Biosciences, Inc., announced today ... to the position of Senior Vice President, Clinical ... immediately. He will report to David J. ... Officer.Dr. Mazzo stated, "Steven has led clinical programs ...
... cellulosic ethanol facility in Florida to serve as ... grant provides State support to project -CAMBRIDGE, Mass., ... VRNM ), a pioneer in the development of ... announced plans to build its first commercial-scale cellulosic ...
Cached Biology Technology:DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 2DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 3Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer 2Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer 3Verenium Announces First Commercial Cellulosic Ethanol Project 2Verenium Announces First Commercial Cellulosic Ethanol Project 3Verenium Announces First Commercial Cellulosic Ethanol Project 4Verenium Announces First Commercial Cellulosic Ethanol Project 5Verenium Announces First Commercial Cellulosic Ethanol Project 6
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Autism Speaks, the nation,s leading autism science and ... Ph.D., its chief science officer, has been named a ... and GQ Magazine who have joined forces, along with ... musicians--rock icon Debbie Harry (Blondie), Bret Michaels, Timbaland, Keri ...
... 16, 2010 Tying in with this year,s conference ... will debut at this year,s TERMIS-North America 2010 Conference ... The TERMIS (Tissue Engineering & Regenerative Medicine International ... Forest Institute for Regenerative Medicine, and chaired by Anthony ...
... San Diego have achieved the "Triple Crown" of ... environment for stem cells that simultaneously provides the ... cell growth and differentiation. Building better microenvironments for ... promises of stem-cell-based regenerative medicine, including cartilage for ...
Cached Biology News:Autism Speaks chief science officer Geraldine Dawson, Ph.D., named 'Rock Star of Science' 2Autism Speaks chief science officer Geraldine Dawson, Ph.D., named 'Rock Star of Science' 3Autism Speaks chief science officer Geraldine Dawson, Ph.D., named 'Rock Star of Science' 4Regenerative medicine workshops to debut at TERMIS North America Annual Conference 2Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 2Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 3Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 4
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: